LENSAR’s (LNSR) Hold Rating Reiterated at Lake Street Capital

Lake Street Capital reissued their hold rating on shares of LENSAR (NASDAQ:LNSR) in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a $15.00 price target on the stock, down from their prior price target of $16.00.

LENSAR Stock Performance

LENSAR stock opened at $14.24 on Monday. The stock has a 50-day simple moving average of $11.56 and a 200 day simple moving average of $8.25. The stock has a market capitalization of $167.88 million, a P/E ratio of -9.75 and a beta of 0.62. LENSAR has a 52 week low of $2.67 and a 52 week high of $17.31.

LENSAR (NASDAQ:LNSR) last issued its earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($1.40). The business had revenue of $16.73 million for the quarter, compared to the consensus estimate of $14.95 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

Hedge Funds Weigh In On LENSAR

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after buying an additional 3,423 shares during the period. Atria Investments Inc raised its holdings in LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock valued at $233,000 after acquiring an additional 5,729 shares during the period. Essex Investment Management Co. LLC lifted its position in LENSAR by 18.3% during the fourth quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after acquiring an additional 6,184 shares during the last quarter. Evernest Financial Advisors LLC bought a new stake in shares of LENSAR during the fourth quarter worth approximately $174,000. Finally, Bailard Inc. acquired a new position in shares of LENSAR in the fourth quarter valued at approximately $181,000. 40.15% of the stock is currently owned by institutional investors and hedge funds.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.